CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Disclosure of COVID-19 Vaccination Status by Physicians

POLICY TYPE  Policy document
DATE        2021-10-22
TOPICS      Physician practice, compensation, forms

Documents
COVID-19 Vaccine Global Intellectual Property Policy

https://policybase.cma.ca/link/policy14458

POLICY TYPE: Policy document
DATE: 2021-10-22
TOPICS: Physician practice, compensation, forms

COVID-19 Vaccine Global Intellectual Property Policy

Policy position recommendation

1. The CMA encourages governments of countries participating in the global vaccine effort to ensure that the global intellectual property (IP) regime supports the equitable and rapid release of COVID-19 vaccines in low- and middle-income countries.

2. The CMA recommends that governments of countries participating in the global vaccine effort to ensure that intellectual property (IP) regimes do not hinder the equitable release of COVID-19 vaccines in low- and middle-income countries.

3. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

4. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

5. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

6. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

7. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

8. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

9. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.

10. The CMA recommendations support the global IP framework for vaccines under Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows for a temporary waiving of certain IP rights to facilitate access to COVID-19 vaccines.
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

https://policybase.cma.ca/link/policy14443

POLICY TYPE: Policy endorsement
DATE: 2021-06-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Dear [Name],

We are writing to urge you to take action in response to the drug shortages occurring across Canada. These shortages have been exacerbated by the COVID-19 pandemic.

As healthcare providers, we have seen firsthand the impact of drug shortages on patient care. Medications that are in short supply can lead to delays in treatment, increased patient risk, and in some cases, preventable hospitalizations.

The shortage of certain drugs, such as opioids and antibiotics, is putting pressure on healthcare systems across the country. The Canadian Medical Association (CMA) has called for a national strategy to address drug shortages.

We believe that government action is necessary to ensure that patients receive the medications they need. This includes providing financial support to manufacturers to increase production, ensuring adequate supply chains, and implementing emergency measures to address urgent needs.

We encourage you to support the recommendations of the CMA's Pre-budget Submission, which calls for a comprehensive approach to addressing drug shortages.

Thank you for your attention to this important issue. We look forward to your response.

Sincerely,

[Name]
Canadian Medical Association

[Signature]

CMA Pre-budget Submission
CMA Policybase - Canadian Medical Association
CMA Pre-budget Submission
https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
Physician practice, compensation, forms
Health information and e-health
Health care and patient safety
Health systems, system funding and performance

Documents
Submission in Response to the Consultation on the Canada Emergency Wage Subsidy: Keeping Medical Clinic Employees on the Payroll
https://policybase.cma.ca/link/policy14258

POLICY TYPE: Parliamentary submission
DATE: 2020-06-05
TOPICS: Physician practice, compensation, forms
Health systems, system funding and performance

Documents

Submission in Response to the Consultation on the Canada Emergency Wage Subsidy: Keeping Medical Clinic Employees on the Payroll
June 5, 2020
Federal measures to recognize the significant contributions of Canada’s front-line health care workers during the COVID-19 pandemic

https://policybase.cma.ca/link/policy14247

POLICY TYPE       Parliamentary submission
DATE              2020-06-02
TOPICS            Physician practice, compensation, forms

Documents

[Image of document page]
Protecting and supporting Canada’s health-care providers during COVID-19
https://policybase.cma.ca/link/policy14260

POLICY TYPE
Parliamentary submission

DATE
2020-03-23

TOPICS
Physician practice, compensation, forms
Health systems, system funding and performance
Health human resources
Rural and remote practice issues
https://policybase.cma.ca/link/policy211

POLICY TYPE Policy document
LAST REVIEWED 2020-02-29
DATE 2000-05-09
REPLACES Promoting medicine as a career for rural high school students (Resolution BD88-03-78)
TOPICS Physician practice, compensation, forms

Documents
The treating physician's role in helping patients return to work after an illness or injury (Update 2013)

https://policybase.cma.ca/link/policy10754

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2013-05-25

REPLACES
The physician's role in helping patients return to work after an illness or injury (Update 2010)

TOPICS
Physician practice, compensation, forms

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
  Population health, health equity, public health

Documents
Standing Committee on Health’s study on violence faced by healthcare workers
https://policybase.cma.ca/link/policy14052

**POLICY TYPE**
Parliamentary submission

**DATE**
2019-05-14

**TOPICS**
Health care and patient safety
Ethics and medical professionalism
Health human resources
Physician practice, compensation, forms

Documents
Auditing Physician Billings

Purpose:
The CMA has described an ongoing commitment to ensure that physician billing practices are in accordance with practice. This principle influences physician practices and the development of national standards for billing.

Background:
A patient’s personal medical record, through an individual’s billing system, is regulated through the billing practices of the individual. Such practices are subject to various types of errors and omissions, which can affect the quality of the record. The billing system may, for example, influence the completeness and accuracy of the record. This may occur through the omission of diagnoses or procedures from the record, leading to errors in the record.

The CMA encourages various types of medical record-keeping practices. These practices include the use of a metastatic or metastatic summary, which provides a summary of the record. This summary includes a list of all diagnoses and procedures that are recorded in the record. The summary includes all diagnoses and procedures, regardless of whether they are included in the record. This practice may help ensure that all diagnoses and procedures are included in the record.

The CMA encourages the use of a metastatic or metastatic summary for the following reasons:

- It provides a comprehensive summary of the record.
- It ensures that all diagnoses and procedures are included in the record.
- It helps to prevent errors in the record.

Billing mistakes can result in underestimation of the cost of medical care and may have serious consequences. The CMA encourages the use of a metastatic or metastatic summary to prevent billing mistakes.

References:

"Billing mistakes can result in underestimation of the cost of medical care and may have serious consequences." Canadian Medical Association Journal, 2019.

"The CMA encourages the use of a metastatic or metastatic summary for the following reasons: It provides a comprehensive summary of the record, it ensures that all diagnoses and procedures are included in the record, and it helps to prevent errors in the record." Canadian Medical Association Journal, 2019.
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), has always recognized the urgency of improving the health status of those individuals suffering from a terminal illness or chronic disease for which conventional therapies have not been effective and for whom cannabis (cannabis) may provide relief.

Famously, there are a number of cases, primarily related to the incident at the beginning of the 20th century, where cannabis use in hospitals was allowed to relieve pain, and the need for hospitalization was minimized.

While the evidence for using cannabis to alleviate conditions has been well supported, the information is available from several government sources.

Paraphrastically, the use of cannabis for seniors in these cases should be approved if it is a regular medication or if cannabis is used as part of a treatment plan.

The CMA’s policy on the promotion of medical services in all provinces should include information on the potential benefits of cannabis for seniors.

This policy outlines the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends the establishment of a national research network.

2. Increase support for research related to cannabis by providing education and training to medical professionals.

3. Increase support for research related to cannabis by medical professionals who are currently working in this field.

4. Increase support for the development of cannabis products that are suitable for medical purposes.

5. Increase support for the development of cannabis products that are suitable for medical purposes.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE     Policy document
LAST REVIEWED  2019-03-03
DATE           2011-05-28
REPLACES       Medication use and seniors
TOPICS         Pharmaceuticals, prescribing, cannabis, drugs
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE Policy document
LAST REVIEWED 2019-03-03
DATE 2012-12-08
TOPICS Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
A new vision for Canada: family practice— the patient’s medical home 2019
https://policybase.cma.ca/link/policy14024

POLICY TYPE: Policy endorsement
DATE: 2019-03-02
TOPICS: Physician practice, compensation, forms
         Health systems, system funding and performance

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-02-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents